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treat patients—that do not fit in the current recommendations—
according our current clinical experience and judgment.
“On the mountains of truth you can never climb in vain: either you
will reach a point higher up today, or you will be training your
powers so that you will be able to climb higher tomorrow.”
Friedrich Nietzsche (20)
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Reply
We are grateful to Dr. Meliga and colleagues for their interest in
our article (1). They raise several important issues that we will
address in a similar order.
The first issue deals with mortality and morbidity after coronary
artery bypass grafting (CABG). As referenced in our article (1), the
mortality for all 5,003 patients with left main stem stenosis
undergoing CABG in the United Kingdom in 2003 was 3% (and
2% in 17,000 without left main stem [LMS] stenosis and 1% in
3,102 patients in the ART [Arterial Revascularisation] trial).
Because enough is known about post-CABG complications, risk
models have been developed to reliably predict their occurrence,
whereas similar data are quite lacking in the percutaneous coronary
intervention (PCI) domain.
In addition, although all postoperative morbidity is unsatisfac-
tory, the reality is that, with the exception of stroke (1% to 2%),
most of it is self-limiting and of little consequence to the patient
over the long term. To equate early postoperative morbidity to the
reduced survival and marked increase in the need for reintervention
with PCI over the long term is arguably a false economy.
Furthermore, long-term mortality from CABG (as well as PCI)
may also reflect other co-existing morbidities, rather than being
attributable to ischemic heart disease.
With regard to bare-metal stents, we stated explicitly that
superior results were obtained in lower-risk patients and that, as
for CABG, the results of PCI would also be disadvantaged by
greater-risk patients. Although Dr. Meliga and colleagues state
that there was no significant difference in mortality between
CABG and PCI in the SoS (Stent or Surgery) trial at 1 year, it
should be noted that, at 5-year follow-up in this study (2), there
was a significant reduction in the risk of mortality with CABG
(6.6%) versus PCI (10.9%), reinforcing the well-known observa-
tion that the benefit of CABG often accrues with time. We agree
with Dr. Meliga and colleagues that substantial heterogeneity
among drug-eluting stent trials precludes pooling them together.
Accordingly, we did not perform a meta-analysis. Our aim was
simply to present all the published studies in the literature.
The complexity and precise anatomical location of distal left
main stem disease, along with its frequently associated multivessel
coronary disease, is not relevant during CABG because bypass
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grafts are placed to the midcoronary vessels, well beyond the left
main and proximal coronary disease (in contradistinction to their
importance for diminishing the likely success of PCI). Further-
more, and again in contrast to PCI, this location of bypass grafts
offers prophylaxis against the development of new disease and
likely contributes to the survival benefit of CABG. The authors
would surely acknowledge that, without repeat intervention for
restenosis in distal left main stem disease, mortality would almost
certainly be increased. In addition, Dr. Meliga and colleagues
themselves have emphasized the crucial impact of distal LMS
stenosis in predicting adverse outcomes with an almost 3-fold
increase in risk in patients with distal LMS stenosis (30%)
compared with those without (11%) at a median of 18 months
(3). Finally, as stated in our article (1), 2 independent groups
have stressed that because restenosis in this critical location is
frequently asymptomatic (4,5), a serial angiographic follow-up
is mandated.
The assertion of Dr. Meliga and colleagues that in all major
institutions all interventional decisions are evaluated by both
interventional cardiologists and cardiac surgeons is not borne
out by the facts. Indeed, many studies explicitly state that the
interventional strategy was decided by the interventional phy-
sician or “according to patient preference.” However, we
strongly agree, and have repeatedly advocated (6,7), that a
multidisciplinary team involving a surgeon should be the
standard of care to ensure real patient choice and genuine
informed consent not only for LMS stenosis but for all
multivessel coronary artery disease.
The authors refer to the study by Bravata et al. (8) of 23
randomized trials of PCI and CABG reporting no difference in
mortality at 10 years. These findings contrast with the findings of
Hoffman et al. (9) who, in a meta-analyses of randomized trials of
PCI and CABG, found a statistically significant survival advantage
for CABG as well as a 4-fold reduction in the need for reinter-
vention. In any event, the vast majority of patients in these trials
had single- or double-vessel coronary artery disease and normal
ventricular function (10), a population in whom it had been well
established more than a decade earlier that there was no prognostic
benefit from surgery (11).
This population is also very different from those who undergo
CABG in clinical practice, and to imply that these trials are
representative of most patients undergoing coronary revasculariza-
tion in clinical practice is misleading (6). Indeed, several large
contemporary registries have consistently shown a marked survival
benefit and freedom from reintervention with CABG in comparison
with PCI (12). The most recent registry (MAIN-COMPARE
[Unprotected Left MAIN Coronary Artery Stenosis: COMparison of
Percutaneous Coronary Angioplasty Versus Surgical Revasculariza-
tion]) showed a mortality hazard ratio of 1.18 (95% confidence
interval: 0.77 to 1.80) for PCI compared with CABG. Although this
difference was not statistically significant (because of inadequate
power), the data are compatible with as much as a 23% improve-
ment or as much as a 80% worsening in mortality with PCI
compared with CABG (13).
As stated in our article (1), although the LEMANS trial is the
only randomized trial comparing PCI versus CABG in 2 groups of
approximately 50 patients, the relatively high operative mortality in
these low-risk patients, allied with the fact that only 72% received
an internal mammary artery graft, suggests that surgery was less
than optimal.
With regards to the justification for randomized trials in LMS
disease, we believe we presented both sides of the arguments in a
fair and balanced manner. We argued that although CABG has
been shown to be superior to medical therapy for left main and
3-vessel disease in randomized controlled trials, this is not the
case for PCI and, because CABG has been consistently dem-
onstrated to be superior to PCI in several large registries, it is
not justifiable to present the information to a patient as there
being equipoise between PCI and CABG. This is particularly
true when viewed from a comparative effectiveness perspective
that is patient centric in focus. Finally, the cogent comments of
Dr. Meliga and colleagues faithfully reflect the current evidence
base: “CABG should remain the preferred revascularization
strategy in good surgical candidates with left main coronary
artery disease” (14).
“The truth is incontrovertible, malice may attack it, ignorance
may deride it, but in the end there it is.”
Winston Churchill (15)
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